-
5
-
-
33847257743
-
-
T.J. Raedler, F.P. Bymaster, R. Tandon, D. Copolov, and B. Dean Mol. Psychiatry 12 2007 232
-
(2007)
Mol. Psychiatry
, vol.12
, pp. 232
-
-
Raedler, T.J.1
Bymaster, F.P.2
Tandon, R.3
Copolov, D.4
Dean, B.5
-
7
-
-
30044435787
-
-
C.J. Langmead, V.A.H. Fry, I.T. Forbes, C.L. Branch, A. Christopoulos, M.D. Wood, and H.J. Herdon Mol. Pharmacol. 69 2006 236
-
(2006)
Mol. Pharmacol.
, vol.69
, pp. 236
-
-
Langmead, C.J.1
Fry, V.A.H.2
Forbes, I.T.3
Branch, C.L.4
Christopoulos, A.5
Wood, M.D.6
Herdon, H.J.7
-
8
-
-
60349091127
-
-
J.N. Heinrich, J.A. Butera, T. Carrick, A. Kramer, D. Kowal, T. Lock, K.L. Marquis, M.H. Pausch, M. Popiolek, S. Sun, E. Tseng, A.J. Uveges, and S.C. Mayer Eur. J. Pharmacol. 605 2009 53
-
(2009)
Eur. J. Pharmacol.
, vol.605
, pp. 53
-
-
Heinrich, J.N.1
Butera, J.A.2
Carrick, T.3
Kramer, A.4
Kowal, D.5
Lock, T.6
Marquis, K.L.7
Pausch, M.H.8
Popiolek, M.9
Sun, S.10
Tseng, E.11
Uveges, A.J.12
Mayer, S.C.13
-
9
-
-
0026611521
-
-
P. Sauerberg, P.H. Olesen, S. Nielsen, S. Treppendahl, M.J. Sheardown, T. Honore, C.H. Mitch, J.S. Ward, A.J. Pike, F.P. Bymaster, B.D. Sawyer, and H.E. Shannon J. Med. Chem. 35 1992 2274
-
(1992)
J. Med. Chem.
, vol.35
, pp. 2274
-
-
Sauerberg, P.1
Olesen, P.H.2
Nielsen, S.3
Treppendahl, S.4
Sheardown, M.J.5
Honore, T.6
Mitch, C.H.7
Ward, J.S.8
Pike, A.J.9
Bymaster, F.P.10
Sawyer, B.D.11
Shannon, H.E.12
-
10
-
-
0031441919
-
-
J.M. Loudon, S.M. Bromidge, F. Brown, M.S. Clark, J.P. Hatcher, J. Hawkins, G.J. Riley, G. Noy, and B.S. Orlek J. Pharmacol. Exp. Ther. 283 1997 1059
-
(1997)
J. Pharmacol. Exp. Ther.
, vol.283
, pp. 1059
-
-
Loudon, J.M.1
Bromidge, S.M.2
Brown, F.3
Clark, M.S.4
Hatcher, J.P.5
Hawkins, J.6
Riley, G.J.7
Noy, G.8
Orlek, B.S.9
-
11
-
-
0030902127
-
-
N.C. Bodick, W.W. Offen, A.I. Levey, N.R. Cutler, S.G. Gauthier, A. Satlin, H.E. Shannon, G.D. Tollefson, K. Rasmussen, F.P. Bymaster, D.J. Hurley, W.Z. Potter, and S.M. Paul Arch. Neurol. 54 1997 465
-
(1997)
Arch. Neurol.
, vol.54
, pp. 465
-
-
Bodick, N.C.1
Offen, W.W.2
Levey, A.I.3
Cutler, N.R.4
Gauthier, S.G.5
Satlin, A.6
Shannon, H.E.7
Tollefson, G.D.8
Rasmussen, K.9
Bymaster, F.P.10
Hurley, D.J.11
Potter, W.Z.12
Paul, S.M.13
-
12
-
-
0036259109
-
-
T.A. Spalding, C. Trotter, N. Skjaerbaek, T.L. Messier, E.A. Currier, E.S. Burstein, D. Li, U. Hacksell, and M.R. Brann Mol. Pharmacol. 61 2002 1297
-
(2002)
Mol. Pharmacol.
, vol.61
, pp. 1297
-
-
Spalding, T.A.1
Trotter, C.2
Skjaerbaek, N.3
Messier, T.L.4
Currier, E.A.5
Burstein, E.S.6
Li, D.7
Hacksell, U.8
Brann, M.R.9
-
13
-
-
53349117101
-
-
T.M. Bridges, A.E. Brady, J.P. Kennedy, R.N. Daniels, N.R. Miller, K. Kim, M.L. Breininger, P.R. Gentry, J.T. Brogan, C.K. Jones, P.J. Conn, and C.W. Lindsley Bioorg. Med. Chem. Lett. 18 2008 5439
-
(2008)
Bioorg. Med. Chem. Lett.
, vol.18
, pp. 5439
-
-
Bridges, T.M.1
Brady, A.E.2
Kennedy, J.P.3
Daniels, R.N.4
Miller, N.R.5
Kim, K.6
Breininger, M.L.7
Gentry, P.R.8
Brogan, J.T.9
Jones, C.K.10
Conn, P.J.11
Lindsley, C.W.12
-
14
-
-
77956170187
-
-
doi:10.1016/j.bmcl.2010.04.128
-
Budzik, B.; Garzya, V.; Shi, D.; Foley, J. J.; Rivero, R. A.; Langmead, C. L.; Watson, J.; Wu, Z.; Forbes, I. T.; Jin, J. Bioorg. Med. Chem. Lett., doi:10.1016/j.bmcl.2010.04.128.
-
Bioorg. Med. Chem. Lett.
-
-
Budzik, B.1
Garzya, V.2
Shi, D.3
Foley, J.J.4
Rivero, R.A.5
Langmead, C.L.6
Watson, J.7
Wu, Z.8
Forbes, I.T.9
Jin, J.10
-
15
-
-
77956174947
-
-
doi:10.1016/j.bmcl.2010.04.127
-
Budzik, B.; Garzya, V.; Shi, D.; Walker, G. W.; Lauchart, Y.; Lucas, A. J.; Rivero, R. A.; Langmead, C. L.; Watson, J.; Wu, Z.; Forbes, I. T.; Jin, J. Bioorg. Med. Chem. Lett., doi:10.1016/j.bmcl.2010.04.127.
-
Bioorg. Med. Chem. Lett.
-
-
Budzik, B.1
Garzya, V.2
Shi, D.3
Walker, G.W.4
Lauchart, Y.5
Lucas, A.J.6
Rivero, R.A.7
Langmead, C.L.8
Watson, J.9
Wu, Z.10
Forbes, I.T.11
Jin, J.12
-
17
-
-
77956174103
-
-
doi:10.1021/ml100105x
-
Budzik, B.; Garzya, V.; Shi, D.; Walker, G.; Woolley-Roberts, M.; Pardoe, J.; Lucas, A.; Tehan, B.; Rivero, R. A.; Langmead, C. J.; Watson, J.; Wu, Z.; Forbes, I. T.; Jin, J. ACS Med. Chem. Lett., doi:10.1021/ml100105x.
-
ACS Med. Chem. Lett.
-
-
Budzik, B.1
Garzya, V.2
Shi, D.3
Walker, G.4
Woolley-Roberts, M.5
Pardoe, J.6
Lucas, A.7
Tehan, B.8
Rivero, R.A.9
Langmead, C.J.10
Watson, J.11
Wu, Z.12
Forbes, I.T.13
Jin, J.14
-
20
-
-
77956181282
-
-
For full experimental procedures and NMR and LC/MS characterisation see Cooper, D. G.; Forbes, I. T.; Garzya, V.; Johnson, D. J.; Stevenson, G. I.; Wyman, P. A. WO2009/037294
-
For full experimental procedures and NMR and LC/MS characterisation see Cooper, D. G.; Forbes, I. T.; Garzya, V.; Johnson, D. J.; Stevenson, G. I.; Wyman, P. A. WO2009/037294.
-
-
-
-
21
-
-
77956174415
-
-
4 cells also stably express Gqi5 chimaeric G-protein. 11 point concentration-response curves were generated. Values are average of at least five experiments
-
4 cells also stably express Gqi5 chimaeric G-protein. 11 point concentration-response curves were generated. Values are average of at least five experiments.
-
-
-
-
22
-
-
77956181096
-
-
Antagonist selectivity was not investigated due to agonist induced desensitisation of the FLIPR assay
-
Antagonist selectivity was not investigated due to agonist induced desensitisation of the FLIPR assay.
-
-
-
-
25
-
-
33644756715
-
-
S.G. Summerfield, A.J. Stevens, L. Cutler, M.D. Carmen-Osuna, B. Hammond, S. Tang, A. Hersey, D.J. Spalding, and P. Jeffrey J. Pharmacol. Exp. Ther. 316 2006 1282
-
(2006)
J. Pharmacol. Exp. Ther.
, vol.316
, pp. 1282
-
-
Summerfield, S.G.1
Stevens, A.J.2
Cutler, L.3
Carmen-Osuna, M.D.4
Hammond, B.5
Tang, S.6
Hersey, A.7
Spalding, D.J.8
Jeffrey, P.9
-
26
-
-
77956176678
-
-
For a full list of assays tested see
-
For a full list of assays tested see http://www.cerep.fr/cerep/users/ pages/catalog/Profiles/catalog.asp.
-
-
-
-
27
-
-
77956177099
-
-
note
-
The novel object recognition (NOR) model was used to assess the effects on recognition memory in rats. Ennaceur and Delacour (Behavioural Brain. Res., 1988, 31, 47) and is a non-rewarded test of spontaneous behaviour based on the differential exploration of novel and familiar objects. The NOR test comprised of two sessions, T1 and T2, each lasting 3 min. On the first test day (T1), following a 3 min habituation to the empty test box, the rat was placed into the annex and 2 identical objects were placed into the test arena. The rat was then returned to the test area and allowed to freely explore the objects for 3 min. On the second day (T2), a similar protocol was adopted, except that one of the 'familiar' objects was substituted for a novel one of the same colour, material and similar size but different shape. In order to detect a potential cognition-enhancing effect an inter-trial interval (ITI) of 24 h between T1 and T2 was used to induce a performance deficit. The objects comprised of black hardened plastic geometric shapes, such as towers and pyramids, that were approximately 6.5 cm high × 6 cm diameter. Exploration was scored as time spent sniffing or licking the objects. Sitting on or climbing over the objects was not considered to be exploratory behaviour. Between trials, objects were cleaned with 70% ethanol to remove olfactory cues. All trials were recorded via camera. Exploration was scored retrospectively by an experimenter blind to the novel object. The presentation of objects was balanced across days, trials and box position (left/right) to minimise bias. Data were expressed as a d1 index (time spent exploring novel object - time spent exp exploring familiar object) and d2 index ([time exploring novel object - time exploring familiar object]/total exploration time). T1 exploration times were also considered since hyperactivity or sedation may confound the results. The d1 and d2 index scores were analyzed using a two-way analysis of variance (ANOVA, object × treatment) followed by planned comparisons for between groups analysis using Statistica version 6 (Statsoft Inc., Tulsa). Data are expressed as mean ± SEM and were considered significant when p <0.05.
-
-
-
|